During the recent session, Editas Medicine Inc (NASDAQ:EDIT)’s traded shares were 1.68 million, with the beta value of the company hitting 1.97. At the last check today, the stock’s price was $1.42, reflecting an intraday gain of 15.45% or $0.19. The 52-week high for the EDIT share is $11.58, that puts it down -715.49 from that peak though still a striking 21.13% gain since the share price plummeted to a 52-week low of $1.12. The company’s market capitalization is $117.21M, and the average intraday trading volume over the past 10 days was 1.37 million shares, and the average trade volume was 2.58 million shares over the past three months.
Editas Medicine Inc (EDIT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.62. EDIT has a Sell rating from 0 analyst(s) out of 9 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.33.
Editas Medicine Inc (NASDAQ:EDIT) trade information
Editas Medicine Inc (EDIT) registered a 15.45% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 15.45% in intraday trading to $1.42, hitting a weekly high. The stock’s 5-day price performance is 13.60%, and it has moved by 16.39% in 30 days. Based on these gigs, the overall price performance for the year is -80.81%. The short interest in Editas Medicine Inc (NASDAQ:EDIT) is 17.09 million shares and it means that shorts have 6.83 day(s) to cover.
The consensus price target of analysts on Wall Street is $9, which implies an increase of 84.22% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $10 respectively. As a result, EDIT is trading at a discount of -604.23% off the target high and -252.11% off the low.
Editas Medicine Inc (EDIT) estimates and forecasts
In the rating firms’ projections, revenue will decrease -47.32% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 37.17M as predicted by 13 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 640.25k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 60.05M and 1.14M respectively. In this case, analysts expect current quarter sales to shrink by -38.10% and then drop by -43.59% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 2.88%. While earnings are projected to return -33.69% in 2025, the next five years will return 15.23% per annum.
EDIT Dividends
Editas Medicine Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Editas Medicine Inc (NASDAQ:EDIT)’s Major holders
Editas Medicine Inc insiders own 0.61% of total outstanding shares while institutional holders control 70.77%, with the float percentage being 71.21%. VANGUARD GROUP INC is the largest shareholder of the company, while 281.0 institutions own stock in it. As of 2024-06-30, the company held over 8.03 million shares (or 9.8032% of all shares), a total value of $37.51 million in shares.
The next largest institutional holding, with 7.78 million shares, is of BLACKROCK INC.’s that is approximately 9.498% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $36.34 million.
Also, the Mutual Funds coming in first place with the largest holdings of Editas Medicine Inc (EDIT) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 2.59 shares. This amounts to just over 3.14 percent of the company’s overall shares, with a $3.72 million market value. The same data shows that the other fund manager holds slightly less at 2.33, or about 2.83% of the stock, which is worth about $3.35 million.
